Try our Advanced Search for more refined results

FTC OK's $324M Akorn Deal For Drugmaker, With Conditions

By Vin Gurrieri (August 4, 2014, 7:41 PM EDT) -- The Federal Trade Commission on Monday agreed to sign off on Akorn Inc.'s $324 million acquisition of private equity-backed niche drug manufacturer VersaPharm Inc. on the condition that Akorn sell its rights to develop and market the generic injectable tuberculosis drug rifampin to address the agency's antitrust concerns....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!